A chimeric antigen receptor T-cell therapy produced a response rate of 71% among patients with relapsed or refractory multiple myeloma, according to phase 1 study results published in The New England Journal of Medicine.
Most patients responded to a single dose of the therapy despite experiencing disease progression after prior B-cell maturation antigen (BCMA)-directed CAR-T, investigators noted.
MCARH109 (Juno Therapeutics/Bristol Myers Squibb) is an investigational CAR T-cell therapy that targets G protein–coupled receptor, class C, group 5, member D (GPRC5D), a protein receptor known
